Radiation oncology (London, England) · 2026
Clinical and prognostic insights into radiation-associated angiosarcoma: a multi-institutional analysis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Harbrücker Melissa, Hoffmann Sebastian, Thiel Johannes Tobias, Jacob-Rehfeld Noelle Samira, Christ Sebastian M, Daigeler Adrien, Duprée Anna, Ehret Felix, Flörcken Anne, Hohenberger Peter, Kasper Bernd, Reißfelder Christoph, Jakob Jens, Kneser Ulrich, Strübing Felix, Striefler Jana Käthe, Roohani Siyer
Аннотация
PURPOSE: To evaluate oncological outcomes and prognostic factors in patients with radiation-associated angiosarcoma (RAAS) treated at referral centers.
METHODS: We conducted a multi-institutional retrospective cohort study of patients with histopathologically confirmed primary or recurrent RAAS treated at four referral centers in Germany. Endpoints were overall survival (OS) and progression-free survival (PFS), estimated using the Kaplan-Meier method. Prognostic factors were assessed using multivariable Cox regression.
RESULTS: Among 71 patients (97.2% female; median age 69 years), 90% had a history of breast cancer treated with radiotherapy (RT). RAAS developed after a mean latency of 7 years, with a median RT dose of 59.4 Gy. Over a median follow-up of 13.0 months, OS reached a median of 41.7 months, with 1- and 2-year rates of 82.9% and 61.7%, respectively. Median PFS was 9.5 months, with 1- and 2-year rates of 43.7% and 27.1%. Larger tumor size (HR 1.09, p = 0.032) and metastatic disease at diagnosis (HR 2.98, p = 0.003) were associated with worse OS.
CONCLUSIONS: RAAS are aggressive, frequently relapsing malignancies occurring years after RT. Larger tumor size and metastatic presentation are associated with worse OS. Multi-institutional and translational studies are needed to clarify disease biology, refine risk factors, and guide treatment strategies.
METHODS: We conducted a multi-institutional retrospective cohort study of patients with histopathologically confirmed primary or recurrent RAAS treated at four referral centers in Germany. Endpoints were overall survival (OS) and progression-free survival (PFS), estimated using the Kaplan-Meier method. Prognostic factors were assessed using multivariable Cox regression.
RESULTS: Among 71 patients (97.2% female; median age 69 years), 90% had a history of breast cancer treated with radiotherapy (RT). RAAS developed after a mean latency of 7 years, with a median RT dose of 59.4 Gy. Over a median follow-up of 13.0 months, OS reached a median of 41.7 months, with 1- and 2-year rates of 82.9% and 61.7%, respectively. Median PFS was 9.5 months, with 1- and 2-year rates of 43.7% and 27.1%. Larger tumor size (HR 1.09, p = 0.032) and metastatic disease at diagnosis (HR 2.98, p = 0.003) were associated with worse OS.
CONCLUSIONS: RAAS are aggressive, frequently relapsing malignancies occurring years after RT. Larger tumor size and metastatic presentation are associated with worse OS. Multi-institutional and translational studies are needed to clarify disease biology, refine risk factors, and guide treatment strategies.